Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers.
Oliver KleinDamien KeeBen MarkmanMichael MichaelCraig UnderhillMatteo S CarlinoLouise JackettCaroline LumClare L ScottAdnan NagrialAndreas BehrenJane Y SoJodie PalmerJonathan S CebonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Combination immunotherapy with ipilimumab and nivolumab demonstrated significant clinical activity in subgroups of patients with advanced NETs including patients with atypical bronchial carcinoid and high-grade pancreatic NENs.